Recombinant; Rabbit anti Human Brd4 Antibody; WB; Unconjugated
| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab091675-10μl | 10μl | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $66.90 | |
| Ab091675-50μl | 50μl | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $199.90 | |
| Ab091675-100μl | 100μl | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $299.90 | |
| Ab091675-1ml | 1ml | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $2,699.90 |
Recombinant; Rabbit anti Human Brd4 Antibody; WB; Unconjugated
| Product Name | Recombinant Brd4 Antibody - Primary antibody, specific to BRD4, Rabbit IgG |
|---|---|
| Synonyms | Brd4 | BRD4_HUMAN | bromodomain containing protein 4 | Bromodomain-containing protein 4 | CAP | chromosome associated protein | HUNK1 | Protein HUNK1 | Brd4 antibody | BRD4-NUT FUSION antibody | BRD4-NUT fusion oncoprotein antibody | BRD4_HUMAN antibody | |
| Specifications & Purity | ExactAb™, Validated, Recombinant, 0.8 mg/mL |
| Host species | Rabbit |
| Specificity | BRD4 |
| Immunogen | A synthetic peptide derived from human Brd4 (AA 140-210) |
| Positive Control | WB: HeLa, HEK293, Jurkat and MDA-MB-231 cell lysates. |
| Conjugation | Unconjugated |
| Grade | ExactAb™, Recombinant, Validated |
| Product Description | Rabbit anti Human Brd4 Antibody, Recombinant, could be used for WB and so on. |
| Isotype | Rabbit IgG |
|---|---|
| SDS-PAGE | 150 kDa |
| Purification Method | Protein A purified |
| Form | Liquid |
| Concentration | 0.8 mg/mL |
| Storage Temp | Store at -20°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at 4°C short term (1-2 weeks). Store at -20°C long term (24 months). Upon delivery aliquot. Avoid freeze/thaw cycle. |
Recombinant Brd4 Antibody (Ab091675) - Western Blot
All lanes: Recombinant Brd4 Antibody (Ab091675) at 1/1000 dilution
Samples: Lysates at 20 µg per lane
Secondary: Goat Anti-Rabbit IgG H&L (HRP) (Ab170144) at 1/20000 dilution
Predicted band size: 152 kDa
Observed band size: 102, 150 kDa
Exposure time: 4.8 s
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Application | Dilution info |
|---|---|
| WB | 1/500-1/1000 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ24F0607509 | Certificate of Analysis | Jun 27, 2024 | Ab091675 |
| ZJ24F0607508 | Certificate of Analysis | Jun 27, 2024 | Ab091675 |
| 1. Filippakopoulos P, Picaud S, Mangos M, Keates T, Lambert JP, Barsyte-Lovejoy D, Felletar I, Volkmer R, Müller S, Pawson T et al.. (2012) Histone recognition and large-scale structural analysis of the human bromodomain family.. Cell, 149 (1): (214-31). [PMID:22464331] |
| 2. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C et al.. (2007) Patterns of somatic mutation in human cancer genomes.. Nature, 446 (7132): (153-8). [PMID:17344846] |
| 3. Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung CW, Chandwani R, Marazzi I, Wilson P, Coste H et al.. (2010) Suppression of inflammation by a synthetic histone mimic.. Nature, 468 (7327): (1119-23). [PMID:21068722] |
| 4. Zhang G, Plotnikov AN, Rusinova E, Shen T, Morohashi K, Joshua J, Zeng L, Mujtaba S, Ohlmeyer M, Zhou MM. (2013) Structure-guided design of potent diazobenzene inhibitors for the BET bromodomains.. J Med Chem, 56 (22): (9251-64). [PMID:24144283] |
| 5. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I et al.. (2010) Selective inhibition of BET bromodomains.. Nature, 468 (7327): (1067-73). [PMID:20871596] |
| 6. Zhang G, Liu R, Zhong Y, Plotnikov AN, Zhang W, Zeng L, Rusinova E, Gerona-Nevarro G, Moshkina N, Joshua J et al.. (2012) Down-regulation of NF-κB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition.. J Biol Chem, 287 (34): (28840-51). [PMID:22645123] |
| 7. Devaiah BN, Lewis BA, Cherman N, Hewitt MC, Albrecht BK, Robey PG, Ozato K, Sims 3rd RJ, Singer DS. (2012) BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain.. Proc Natl Acad Sci USA, 109 (18): (6927-32). [PMID:22509028] |
| 8. Chung CW, Coste H, White JH, Mirguet O, Wilde J, Gosmini RL, Delves C, Magny SM, Woodward R, Hughes SA et al.. (2011) Discovery and characterization of small molecule inhibitors of the BET family bromodomains.. J Med Chem, 54 (11): (3827-38). [PMID:21568322] |
| 9. Hewings DS, Wang M, Philpott M, Fedorov O, Uttarkar S, Filippakopoulos P, Picaud S, Vuppusetty C, Marsden B, Knapp S et al.. (2011) 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands.. J Med Chem, 54 (19): (6761-70). [PMID:21851057] |
| 10. Hewings DS, Fedorov O, Filippakopoulos P, Martin S, Picaud S, Tumber A, Wells C, Olcina MM, Freeman K, Gill A et al.. (2013) Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands.. J Med Chem, 56 (8): (3217-27). [PMID:23517011] |
| 11. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, Robson SC, Chung CW, Hopf C, Savitski MM et al.. (2011) Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.. Nature, 478 (7370): (529-33). [PMID:21964340] |
| 12. Fish PV, Filippakopoulos P, Bish G, Brennan PE, Bunnage ME, Cook AS, Federov O, Gerstenberger BS, Jones H, Knapp S et al.. (2012) Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.. J Med Chem, 55 (22): (9831-7). [PMID:23095041] |
| 13. Ciceri P, Müller S, O'Mahony A, Fedorov O, Filippakopoulos P, Hunt JP, Lasater EA, Pallares G, Picaud S, Wells C et al.. (2014) Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.. Nat Chem Biol, 10 (4): (305-12). [PMID:24584101] |
| 14. Drouin L, McGrath S, Vidler LR, Chaikuad A, Monteiro O, Tallant C, Philpott M, Rogers C, Fedorov O, Liu M et al.. (2015) Structure Enabled Design of BAZ2-ICR, A Chemical Probe Targeting the Bromodomains of BAZ2A and BAZ2B.. J Med Chem, 58 (5): (2553-9). [PMID:25719566] |
| 15. Picaud S, Strocchia M, Terracciano S, Lauro G, Mendez J, Daniels DL, Riccio R, Bifulco G, Bruno I, Filippakopoulos P. (2015) 9H-Purine Scaffold Reveals Induced-Fit Pocket Plasticity of the BRD9 Bromodomain.. J Med Chem, 58 (6): (2718-36). [PMID:25703523] |
| 16. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions.. Science, 325 (5942): (834-40). [PMID:19608861] |
| 17. Theodoulou NH, Bamborough P, Bannister AJ, Becher I, Bit RA, Che KH, Chung CW, Dittmann A, Drewes G, Drewry DH et al.. (2016) Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition.. J Med Chem, 59 (4): (1425-39). [PMID:25856009] |
| 18. Demont EH, Chung CW, Furze RC, Grandi P, Michon AM, Wellaway C, Barrett N, Bridges AM, Craggs PD, Diallo H et al.. (2015) Fragment-Based Discovery of Low-Micromolar ATAD2 Bromodomain Inhibitors.. J Med Chem, 58 (14): (5649-73). [PMID:26155854] |
| 19. McLure KG, Gesner EM, Tsujikawa L, Kharenko OA, Attwell S, Campeau E, Wasiak S, Stein A, White A, Fontano E et al.. (2013) RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist.. PLoS ONE, 8 (12): (e83190). [PMID:24391744] |
| 20. Fedorov O, Lingard H, Wells C, Monteiro OP, Picaud S, Keates T, Yapp C, Philpott M, Martin SJ, Felletar I et al.. (2014) [1,2,4]triazolo[4,3-a]phthalazines: inhibitors of diverse bromodomains.. J Med Chem, 57 (2): (462-76). [PMID:24313754] |
| 21. Martin LJ, Koegl M, Bader G, Cockcroft XL, Fedorov O, Fiegen D, Gerstberger T, Hofmann MH, Hohmann AF, Kessler D et al.. (2016) Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor.. J Med Chem, 59 (10): (4462-75). [PMID:26914985] |
| 22. Shortt J, Hsu AK, Martin BP, Doggett K, Matthews GM, Doyle MA, Ellul J, Jockel TE, Andrews DM, Hogg SJ et al.. (2014) The drug vehicle and solvent N-methylpyrrolidone is an immunomodulator and antimyeloma compound.. Cell Rep, 7 (4): (1009-19). [PMID:24813887] |
| 23. Liu S, Yosief HO, Dai L, Huang H, Dhawan G, Zhang X, Muthengi AM, Roberts J, Buckley DL, Perry JA et al.. (2018) Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors.. J Med Chem, 61 (17): (7785-7795). [PMID:30125504] |
| 24. Winter GE, Mayer A, Buckley DL, Erb MA, Roderick JE, Vittori S, Reyes JM, di Iulio J, Souza A, Ott CJ et al.. (2017) BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment.. Mol Cell, 67 (1): (5-18.e19). [PMID:28673542] |
| 25. Raina K, Lu J, Qian Y, Altieri M, Gordon D, Rossi AM, Wang J, Chen X, Dong H, Siu K et al.. (2016) PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer.. Proc Natl Acad Sci USA, 113 (26): (7124-9). [PMID:27274052] |
| 26. Chan KH, Zengerle M, Testa A, Ciulli A. (2018) Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds.. J Med Chem, 61 (2): (504-513). [PMID:28595007] |
| 27. Ferguson FM, Liu Y, Harshbarger W, Huang L, Wang J, Deng X, Capuzzi SJ, Muratov EN, Tropsha A, Muthuswamy S et al.. (2020) Synthesis and Structure-Activity Relationships of DCLK1 Kinase Inhibitors Based on a 5,11-Dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-one Scaffold.. J Med Chem, 63 (14): (7817-7826). [PMID:32530623] |
| 28. Francis Impens,Lilliana Radoshevich,Pascale Cossart,David Ribet. (2014-08-13) Mapping of SUMO sites and analysis of SUMOylation changes induced by external stimuli.. Proceedings of the National Academy of Sciences of the United States of America, 111 ((34)): (12432-12437). [PMID:25114211] |
| 29. Tomomi Noguchi-Yachide,Taki Sakai,Yuichi Hashimoto,Takao Yamaguchi. (2015-02-14) Discovery and structure-activity relationship studies of N6-benzoyladenine derivatives as novel BRD4 inhibitors.. Bioorganic & medicinal chemistry, 23 ((5)): (953-959). [PMID:25678016] |
| 30. Laura E Jennings,Matthias Schiedel,David S Hewings,Sarah Picaud,Corentine M C Laurin,Paul A Bruno,Joseph P Bluck,Amy R Scorah,Larissa See,Jessica K Reynolds,Mustafa Moroglu,Ishna N Mistry,Amy Hicks,Pavel Guzanov,James Clayton,Charles N G Evans,Giulia Stazi,Philip C Biggin,Anna K Mapp,Ester M Hammond,Philip G Humphreys,Panagis Filippakopoulos,Stuart J Conway. (2018-05-20) BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.. Bioorganic & medicinal chemistry, 26 ((11)): (2937-2957). [PMID:29776834] |
| 31. Sharon Gauci,Andreas O Helbig,Monique Slijper,Jeroen Krijgsveld,Albert J R Heck,Shabaz Mohammed. (2009-05-06) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.. Analytical chemistry, 81 ((11)): (4493-4501). [PMID:19413330] |
| 32. Anand Divakaran,Siva K Talluri,Alex M Ayoub,Neeraj K Mishra,Huarui Cui,John C Widen,Norbert Berndt,Jin-Yi Zhu,Angela S Carlson,Joseph J Topczewski,Ernst K Schonbrunn,Daniel A Harki,William C K Pomerantz. (2018-09-27) Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor.. Journal of medicinal chemistry, 61 ((20)): (9316-9334). [PMID:30253095] |
| 33. Sunose M, Bell K, Ellard K, Bergamini G, Neubauer G, Werner T, Ramsden N.. (2012) Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.. Bioorg Med Chem Lett, 22 (14): (4613-4618). [PMID:22726925] |
| 34. Mirguet O, Gosmini R, Toum J, Clément CA, Barnathan M, Brusq JM, Mordaunt JE, Grimes RM, Crowe M, Pineau O, Ajakane M, Daugan A, Jeffrey P, Cutler L, Haynes AC, Smithers NN, Chung CW, Bamborough P, Uings IJ, Lewis A, Witherington J, Parr N, Prinjha RK, Nicodème E.. (2013) Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.. J Med Chem, 56 (19): (7501-7515). [PMID:24015967] |
| 35. Vidler LR, Filippakopoulos P, Fedorov O, Picaud S, Martin S, Tomsett M, Woodward H, Brown N, Knapp S, Hoelder S.. (2013) Discovery of novel small-molecule inhibitors of BRD4 using structure-based virtual screening.. J Med Chem, 56 (20): (8073-8088). [PMID:24090311] |
| 36. Hay D, Fedorov O, Filippakopoulos P, Martin S, Philpott M, Picaud S, Hewings DS, Uttakar S, Heightman TD, Conway SJ, Knapp S, Brennan PE.. (2013) The design and synthesis of 5- and 6-isoxazolylbenzimidazoles as selective inhibitors of the BET bromodomains.. Medchemcomm, 4 (1): (140-144). [PMID:26682033] |
| 37. Gosmini R, Nguyen VL, Toum J, Simon C, Brusq JM, Krysa G, Mirguet O, Riou-Eymard AM, Boursier EV, Trottet L, Bamborough P, Clark H, Chung CW, Cutler L, Demont EH, Kaur R, Lewis AJ, Schilling MB, Soden PE, Taylor S, Walker AL, Walker MD, Prinjha RK, Nicodème E.. (2014) The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor.. J Med Chem, 57 (19): (8111-8131). [PMID:25249180] |
| 38. McKeown MR, Shaw DL, Fu H, Liu S, Xu X, Marineau JJ, Huang Y, Zhang X, Buckley DL, Kadam A, Zhang Z, Blacklow SC, Qi J, Zhang W, Bradner JE.. (2014) Biased multicomponent reactions to develop novel bromodomain inhibitors.. J Med Chem, 57 (21): (9019-9027). [PMID:25314271] |
| 39. Ran X, Zhao Y, Liu L, Bai L, Yang CY, Zhou B, Meagher JL, Chinnaswamy K, Stuckey JA, Wang S.. (2015) Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.. J Med Chem, 58 (12): (4927-4939). [PMID:26080064] |
| 40. Duffy BC, Liu S, Martin GS, Wang R, Hsia MM, Zhao H, Guo C, Ellis M, Quinn JF, Kharenko OA, Norek K, Gesner EM, Young PR, McLure KG, Wagner GS, Lakshminarasimhan D, White A, Suto RK, Hansen HC, Kitchen DB.. (2015) Discovery of a new chemical series of BRD4(1) inhibitors using protein-ligand docking and structure-guided design.. Bioorg Med Chem Lett, 25 (14): (2818-2823). [PMID:26022843] |
| 41. Chen P, Chaikuad A, Bamborough P, Bantscheff M, Bountra C, Chung CW, Fedorov O, Grandi P, Jung D, Lesniak R, Lindon M, Müller S, Philpott M, Prinjha R, Rogers C, Selenski C, Tallant C, Werner T, Willson TM, Knapp S, Drewry DH.. (2016) Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B.. J Med Chem, 59 (4): (1410-1424). [PMID:25799074] |
| 42. Baud MG, Lin-Shiao E, Zengerle M, Tallant C, Ciulli A.. (2016) New Synthetic Routes to Triazolo-benzodiazepine Analogues: Expanding the Scope of the Bump-and-Hole Approach for Selective Bromo and Extra-Terminal (BET) Bromodomain Inhibition.. J Med Chem, 59 (4): (1492-1500). [PMID:26367539] |
| 43. Palmer WS, Poncet-Montange G, Liu G, Petrocchi A, Reyna N, Subramanian G, Theroff J, Yau A, Kost-Alimova M, Bardenhagen JP, Leo E, Shepard HE, Tieu TN, Shi X, Zhan Y, Zhao S, Barton MC, Draetta G, Toniatti C, Jones P, Geck Do M, Andersen JN.. (2016) Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor.. J Med Chem, 59 (4): (1440-1454). [PMID:26061247] |
| 44. Romero FA, Taylor AM, Crawford TD, Tsui V, Côté A, Magnuson S.. (2016) Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors.. J Med Chem, 59 (4): (1271-1298). [PMID:26572217] |
| 45. Hügle M, Lucas X, Weitzel G, Ostrovskyi D, Breit B, Gerhardt S, Einsle O, Günther S, Wohlwend D.. (2016) 4-Acyl Pyrrole Derivatives Yield Novel Vectors for Designing Inhibitors of the Acetyl-Lysine Recognition Site of BRD4(1).. J Med Chem, 59 (4): (1518-1530). [PMID:26731611] |
| 46. Sutherell CL, Tallant C, Monteiro OP, Yapp C, Fuchs JE, Fedorov O, Siejka P, Müller S, Knapp S, Brenton JD, Brennan PE, Ley SV.. (2016) Identification and Development of 2,3-Dihydropyrrolo[1,2-a]quinazolin-5(1H)-one Inhibitors Targeting Bromodomains within the Switch/Sucrose Nonfermenting Complex.. J Med Chem, 59 (10): (5095-5101). [PMID:27119626] |
| 47. Ren C, Smith SG, Yap K, Li S, Li J, Mezei M, Rodriguez Y, Vincek A, Aguilo F, Walsh MJ, Zhou MM.. (2016) Structure-Guided Discovery of Selective Antagonists for the Chromodomain of Polycomb Repressive Protein CBX7.. ACS Med Chem Lett, 7 (6): (601-605). [PMID:27326334] |
| 48. Li J, Wang P, Zhou B, Shi J, Liu J, Li X, Fan L, Zheng Y, Ouyang L.. (2016) Development of 4,5-dihydro-benzodiazepinone derivatives as a new chemical series of BRD4 inhibitors.. Eur J Med Chem, 121 (294-299). [PMID:27266999] |
| 49. Myrianthopoulos V, Gaboriaud-Kolar N, Tallant C, Hall ML, Grigoriou S, Brownlee PM, Fedorov O, Rogers C, Heidenreich D, Wanior M, Drosos N, Mexia N, Savitsky P, Bagratuni T, Kastritis E, Terpos E, Filippakopoulos P, Müller S, Skaltsounis AL, Downs JA, Knapp S, Mikros E.. (2016) Discovery and Optimization of a Selective Ligand for the Switch/Sucrose Nonfermenting-Related Bromodomains of Polybromo Protein-1 by the Use of Virtual Screening and Hydration Analysis.. J Med Chem, 59 (19): (8787-8803). [PMID:27617704] |
| 50. Crawford TD, Romero FA, Lai KW, Tsui V, Taylor AM, de Leon Boenig G, Noland CL, Murray J, Ly J, Choo EF, Hunsaker TL, Chan EW, Merchant M, Kharbanda S, Gascoigne KE, Kaufman S, Beresini MH, Liao J, Liu W, Chen KX, Chen Z, Conery AR, Côté A, Jayaram H, Jiang Y, Kiefer JR, Kleinheinz T, Li Y, Maher J, Pardo E, Poy F, Spillane KL, Wang F, Wang J, Wei X, Xu Z, Xu Z, Yen I, Zawadzke L, Zhu X, Bellon S, Cummings R, Cochran AG, Albrecht BK, Magnuson S.. (2016) Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300.. J Med Chem, 59 (23): (10549-10563). [PMID:27682507] |
| 51. Sun Z, Zhang H, Chen Z, Xie Y, Jiang H, Chen L, Ding H, Zhang Y, Jiang H, Zheng M, Luo C.. (2017) Discovery of novel BRD4 inhibitors by high-throughput screening, crystallography, and cell-based assays.. Bioorg Med Chem Lett, 27 (9): (2003-2009). [PMID:28347667] |
| 52. Mao R, Shao J, Zhu K, Zhang Y, Ding H, Zhang C, Shi Z, Jiang H, Sun D, Duan W, Luo C.. (2017) Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization.. J Med Chem, 60 (14): (6289-6304). [PMID:28650658] |
| 53. Ayoub AM, Hawk LML, Herzig RJ, Jiang J, Wisniewski AJ, Gee CT, Zhao P, Zhu JY, Berndt N, Offei-Addo NK, Scott TG, Qi J, Bradner JE, Ward TR, Schönbrunn E, Georg GI, Pomerantz WCK.. (2017) BET Bromodomain Inhibitors with One-Step Synthesis Discovered from Virtual Screen.. J Med Chem, 60 (12): (4805-4817). [PMID:28535045] |
| 54. Liu G, Huang W, Wang J, Liu X, Yang J, Zhang Y, Geng Y, Tan W, Zhang A.. (2017) Discovery of Novel Macrocyclic Hedgehog Pathway Inhibitors Acting by Suppressing the Gli-Mediated Transcription.. J Med Chem, 60 (19): (8218-8245). [PMID:28873303] |
| 55. Ouyang L, Zhang L, Liu J, Fu L, Yao D, Zhao Y, Zhang S, Wang G, He G, Liu B.. (2017) Discovery of a Small-Molecule Bromodomain-Containing Protein 4 (BRD4) Inhibitor That Induces AMP-Activated Protein Kinase-Modulated Autophagy-Associated Cell Death in Breast Cancer.. J Med Chem, 60 (24): (9990-10012). [PMID:29172540] |
| 56. Hasvold LA, Sheppard GS, Wang L, Fidanze SD, Liu D, Pratt JK, Mantei RA, Wada CK, Hubbard R, Shen Y, Lin X, Huang X, Warder SE, Wilcox D, Li L, Buchanan FG, Smithee L, Albert DH, Magoc TJ, Park CH, Petros AM, Panchal SC, Sun C, Kovar P, Soni NB, Elmore SW, Kati WM, McDaniel KF.. (2017) Methylpyrrole inhibitors of BET bromodomains.. Bioorg Med Chem Lett, 27 (10): (2225-2233). [PMID:28268136] |
| 57. Liu Z, Wang P, Chen H, Wold EA, Tian B, Brasier AR, Zhou J.. (2017) Drug Discovery Targeting Bromodomain-Containing Protein 4.. J Med Chem, 60 (11): (4533-4558). [PMID:28195723] |
| 58. Shao M, He L, Zheng L, Huang L, Zhou Y, Wang T, Chen Y, Shen M, Wang F, Yang Z, Chen L.. (2017) Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors.. Bioorg Med Chem Lett, 27 (17): (4051-4055). [PMID:28765013] |
| 59. Ali I, Lee J, Go A, Choi G, Lee K.. (2017) Discovery of novel [1,2,4]triazolo[4,3-a]quinoxaline aminophenyl derivatives as BET inhibitors for cancer treatment.. Bioorg Med Chem Lett, 27 (20): (4606-4613). [PMID:28939121] |
| 60. Crawford TD, Audia JE, Bellon S, Burdick DJ, Bommi-Reddy A, Côté A, Cummings RT, Duplessis M, Flynn EM, Hewitt M, Huang HR, Jayaram H, Jiang Y, Joshi S, Kiefer JR, Murray J, Nasveschuk CG, Neiss A, Pardo E, Romero FA, Sandy P, Sims RJ, Tang Y, Taylor AM, Tsui V, Wang J, Wang S, Wang Y, Xu Z, Zawadzke L, Zhu X, Albrecht BK, Magnuson SR, Cochran AG.. (2017) GNE-886: A Potent and Selective Inhibitor of the Cat Eye Syndrome Chromosome Region Candidate 2 Bromodomain (CECR2).. ACS Med Chem Lett, 8 (7): (737-741). [PMID:28740608] |
| 61. Xiang Q, Wang C, Zhang Y, Xue X, Song M, Zhang C, Li C, Wu C, Li K, Hui X, Zhou Y, Smaill JB, Patterson AV, Wu D, Ding K, Xu Y.. (2018) Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer.. Eur J Med Chem, 147 (238-252). [PMID:29448139] |
| 62. Zhao Y, Zhou B, Bai L, Liu L, Yang CY, Meagher JL, Stuckey JA, McEachern D, Przybranowski S, Wang M, Ran X, Aguilar A, Hu Y, Kampf JW, Li X, Zhao T, Li S, Wen B, Sun D, Wang S.. (2018) Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor.. J Med Chem, 61 (14): (6110-6120). [PMID:30015487] |
| 63. Liu Z, Tian B, Chen H, Wang P, Brasier AR, Zhou J.. (2018) Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation.. Eur J Med Chem, 151 (450-461). [PMID:29649741] |
| 64. Feng Y, Xiao S, Chen Y, Jiang H, Liu N, Luo C, Chen S, Chen H.. (2018) Design, synthesis and biological evaluation of benzo[cd]indol-2(1H)-ones derivatives as BRD4 inhibitors.. Eur J Med Chem, 152 (264-273). [PMID:29730189] |
| 65. Xue X, Zhang Y, Wang C, Zhang M, Xiang Q, Wang J, Wang A, Li C, Zhang C, Zou L, Wang R, Wu S, Lu Y, Chen H, Ding K, Li G, Xu Y.. (2018) Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer.. Eur J Med Chem, 152 (542-559). [PMID:29758518] |
| 66. Zhao Y, Bai L, Liu L, McEachern D, Stuckey JA, Meagher JL, Yang CY, Ran X, Zhou B, Hu Y, Li X, Wen B, Zhao T, Li S, Sun D, Wang S.. (2017) Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor.. J Med Chem, 60 (9): (3887-3901). [PMID:28463487] |
| 67. Law RP, Atkinson SJ, Bamborough P, Chung CW, Demont EH, Gordon LJ, Lindon M, Prinjha RK, Watson AJB, Hirst DJ.. (2018) Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.. J Med Chem, 61 (10): (4317-4334). [PMID:29656650] |
| 68. Zhou B, Hu J, Xu F, Chen Z, Bai L, Fernandez-Salas E, Lin M, Liu L, Yang CY, Zhao Y, McEachern D, Przybranowski S, Wen B, Sun D, Wang S.. (2018) Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.. J Med Chem, 61 (2): (462-481). [PMID:28339196] |
| 69. Xiang Q, Zhang Y, Li J, Xue X, Wang C, Song M, Zhang C, Wang R, Li C, Wu C, Zhou Y, Yang X, Li G, Ding K, Xu Y.. (2018) Y08060: A Selective BET Inhibitor for Treatment of Prostate Cancer.. ACS Med Chem Lett, 9 (3): (262-267). [PMID:29541371] |
| 70. Wiedemann B, Weisner J, Rauh D.. (2018) Chemical modulation of transcription factors.. Medchemcomm, 9 (8): (1249-1272). [PMID:30151079] |
| 71. Chen Z, Zhang H, Liu S, Xie Y, Jiang H, Lu W, Xu H, Yue L, Zhang Y, Ding H, Zheng M, Yu K, Chen K, Jiang H, Luo C.. (2017) Discovery of novel trimethoxy-ring BRD4 bromodomain inhibitors: AlphaScreen assay, crystallography and cell-based assay.. Medchemcomm, 8 (6): (1322-1331). [PMID:30108844] |
| 72. Zhu J, Zhou C, Caflisch A.. (2018) Structure-based discovery of selective BRPF1 bromodomain inhibitors.. Eur J Med Chem, 155 (337-352). [PMID:29902720] |
| 73. Yang Y, Chen P, Zhao L, Zhang F, Zhang H, Zhou J.. (2019) Pharmacokinetics-Driven Optimization of 7-Methylimidazo[1,5-a]pyrazin-8(7H)-one as Novel BRD4 Inhibitors.. ACS Med Chem Lett, 10 (12): (1680-1685). [PMID:31857846] |
| 74. Ma QS, Yao Y, Zheng YC, Feng S, Chang J, Yu B, Liu HM.. (2019) Ligand-based design, synthesis and biological evaluation of xanthine derivatives as LSD1/KDM1A inhibitors.. Eur J Med Chem, 162 (555-567). [PMID:30472603] |
| 75. Xing J, Zhang R, Jiang X, Hu T, Wang X, Qiao G, Wang J, Yang F, Luo X, Chen K, Shen J, Luo C, Jiang H, Zheng M.. (2019) Rational design of 5-((1H-imidazol-1-yl)methyl)quinolin-8-ol derivatives as novel bromodomain-containing protein 4 inhibitors.. Eur J Med Chem, 163 (281-294). [PMID:30529546] |
| 76. Wan Y, Li Y, Yan C, Yan M, Tang Z.. (2019) Indole: A privileged scaffold for the design of anti-cancer agents.. Eur J Med Chem, 183 (111691-111691). [PMID:31536895] |
| 77. Pan Z, Li X, Wang Y, Jiang Q, Jiang L, Zhang M, Zhang N, Wu F, Liu B, He G.. (2020) Discovery of Thieno[2,3-d]pyrimidine-Based Hydroxamic Acid Derivatives as Bromodomain-Containing Protein 4/Histone Deacetylase Dual Inhibitors Induce Autophagic Cell Death in Colorectal Carcinoma Cells.. J Med Chem, 63 (7): (3678-3700). [PMID:32153186] |
| 78. Jiang F, Hu Q, Zhang Z, Li H, Li H, Zhang D, Li H, Ma Y, Xu J, Chen H, Cui Y, Zhi Y, Zhang Y, Xu J, Zhu J, Lu T, Chen Y.. (2019) Discovery of Benzo[cd]indol-2(1H)-ones and Pyrrolo[4,3,2-de]quinolin-2(1H)-ones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain with Potential High Efficiency against Acute Gouty Arthritis.. J Med Chem, 62 (24): (11080-11107). [PMID:31789032] |
| 79. Yu J, Zhou P, Hu M, Yang L, Yan G, Xu R, Deng Y, Li X, Chen Y.. (2019) Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants.. Eur J Med Chem, 182 (111608-111608). [PMID:31437779] |
| 80. Carlson AS, Cui H, Divakaran A, Johnson JA, Brunner RM, Pomerantz WCK, Topczewski JJ.. (2019) Systematically Mitigating the p38α Activity of Triazole-based BET Inhibitors.. ACS Med Chem Lett, 10 (9): (1296-1301). [PMID:31531200] |
| 81. Duan Y, Guan Y, Qin W, Zhai X, Yu B, Liu H.. (2018) Targeting Brd4 for cancer therapy: inhibitors and degraders.. Medchemcomm, 9 (11): (1779-1802). [PMID:30542529] |
| 82. Qin C, Hu Y, Zhou B, Fernandez-Salas E, Yang CY, Liu L, McEachern D, Przybranowski S, Wang M, Stuckey J, Meagher J, Bai L, Chen Z, Lin M, Yang J, Ziazadeh DN, Xu F, Hu J, Xiang W, Huang L, Li S, Wen B, Sun D, Wang S.. (2018) Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression.. J Med Chem, 61 (15): (6685-6704). [PMID:30019901] |
| 83. Papatzimas JW, Gorobets E, Maity R, Muniyat MI, MacCallum JL, Neri P, Bahlis NJ, Derksen DJ.. (2019) From Inhibition to Degradation: Targeting the Antiapoptotic Protein Myeloid Cell Leukemia 1 (MCL1).. J Med Chem, 62 (11): (5522-5540). [PMID:31117518] |
| 84. Rong J, Feng ZZ, Shi YJ, Ren J, Xu Y, Wang NY, Xue Q, Liu KL, Zhou SY, Wei W, Yu LT.. (2019) Design, synthesis and biological evaluation of 3,5-dimethylisoxazole and pyridone derivatives as BRD4 inhibitors.. Bioorg Med Chem Lett, 29 (19): (126577-126577). [PMID:31421967] |
| 85. Kim SA, Go A, Jo SH, Park SJ, Jeon YU, Kim JE, Lee HK, Park CH, Lee CO, Park SG, Kim P, Park BC, Cho SY, Kim S, Ha JD, Kim JH, Hwang JY.. (2019) A novel cereblon modulator for targeted protein degradation.. Eur J Med Chem, 166 (65-74). [PMID:30684871] |
| 86. Watts E, Heidenreich D, Tucker E, Raab M, Strebhardt K, Chesler L, Knapp S, Bellenie B, Hoelder S.. (2019) Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity.. J Med Chem, 62 (5): (2618-2637). [PMID:30789735] |
| 87. Zheng P, Zhang J, Ma H, Yuan X, Chen P, Zhou J, Zhang H.. (2019) Design, synthesis and biological evaluation of imidazo[1,5-a]pyrazin-8(7H)-one derivatives as BRD9 inhibitors.. Bioorg Med Chem, 27 (7): (1391-1404). [PMID:30824168] |
| 88. Moustakim M, Clark PGK, Hay DA, Dixon DJ, Brennan PE.. (2016) Chemical probes and inhibitors of bromodomains outside the BET family.. Medchemcomm, 7 (12): (2246-2264). [PMID:29170712] |
| 89. Jiang F, Wei Q, Li H, Li H, Cui Y, Ma Y, Chen H, Cao P, Lu T, Chen Y.. (2020) Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies.. Bioorg Med Chem, 28 (1): (115181-115181). [PMID:31767403] |
| 90. Li Y, Zhao J, Gutgesell LM, Shen Z, Ratia K, Dye K, Dubrovskyi O, Zhao H, Huang F, Tonetti DA, Thatcher GRJ, Xiong R.. (2020) Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib.. J Med Chem, 63 (13): (7186-7210). [PMID:32453591] |
| 91. Casalvieri KA, Matheson CJ, Backos DS, Reigan P.. (2020) Substituted pteridinones as p90 ribosomal S6 protein kinase (RSK) inhibitors: A structure-activity study.. Bioorg Med Chem, 28 (5): (115303-115303). [PMID:31982240] |
| 92. Yang SM,Yoshioka M,Strovel JW,Urban DJ,Hu X,Hall MD,Jadhav A,Maloney DJ. (2019) Lead optimization and efficacy evaluation of quinazoline-based BET family inhibitors for potential treatment of cancer and inflammatory diseases.. Bioorg Med Chem Lett, 29 (10.0): (1220-1226). [PMID:30905542] |
| 93. Yang Y,Chen P,Zhao L,Zhang B,Xu C,Zhang H,Zhou J. (2021) Design, synthesis and biological evaluation of imidazolopyridone derivatives as novel BRD4 inhibitors.. Bioorg Med Chem, 29 (115857-115857). [PMID:33191086] |
| 94. Bi X,Chen Y,Sun Z,Lu W,Xu P,Lu T,Ding H,Zhang N,Jiang H,Chen K,Zhou B,Luo C. (2020) Structure-based drug optimization and biological evaluation of tetrahydroquinolin derivatives as selective and potent CBP bromodomain inhibitors.. Bioorg Med Chem Lett, 30 (22): (127480-127480). [PMID:32882416] |
| 95. Xu Y,Zhang XJ,Li WB,Wang XR,Wang S,Qiao XP,Chen SW. (2020) Design, synthesis and biological evaluation of indole-2-one derivatives as potent BRD4 inhibitors.. Eur J Med Chem, 208 (112780-112780). [PMID:32883643] |
| 96. Taylor AM,Vaswani RG,Gehling VS,Hewitt MC,Leblanc Y,Audia JE,Bellon S,Cummings RT,Côté A,Harmange JC,Jayaram H,Joshi S,Lora JM,Mertz JA,Neiss A,Pardo E,Nasveschuk CG,Poy F,Sandy P,Setser JW,Sims RJ,Tang Y,Albrecht BK. (2016) Discovery of Benzotriazolo[4,3-d][1,4]diazepines as Orally Active Inhibitors of BET Bromodomains.. ACS Med Chem Lett, 7 (2.0): (145-150). [PMID:26985289] |
| 97. Hügle M,Regenass P,Warstat R,Hau M,Schmidtkunz K,Lucas X,Wohlwend D,Einsle O,Jung M,Breit B,Günther S. (2020) 4-Acyl Pyrroles as Dual BET-BRD7/9 Bromodomain Inhibitors Address BETi Insensitive Human Cancer Cell Lines.. J Med Chem, 63 (24.0): (15603-15620). [PMID:33275431] |
| 98. Sato M,Kondo T,Kohno Y,Seto S. (2021) Discovery of benzo[f]pyrido[4,3-b][1,4]oxazepin-10-one derivatives as orally available bromodomain and extra-terminal domain (BET) inhibitors with efficacy in an in vivo psoriatic animal model.. Bioorg Med Chem, 34 (116015-116015). [PMID:33549905] |
| 99. Yang Y,Fang L,Chen P,Zhang H,Zhou J. (2020) Identification of 3,5-Dimethylisoxazole Derivatives as BRD4 Inhibitors for the Treatment of Colorectal Cancer.. ACS Med Chem Lett, 11 (11): (2174-2181). [PMID:33214826] |
| 100. He ZX,Wei BF,Zhang X,Gong YP,Ma LY,Zhao W. (2021) Current development of CBP/p300 inhibitors in the last decade.. Eur J Med Chem, 209 (112861-112861). [PMID:33045661] |
| 101. Zhang M,Zhang Y,Song M,Xue X,Wang J,Wang C,Zhang C,Li C,Xiang Q,Zou L,Wu X,Wu C,Dong B,Xue W,Zhou Y,Chen H,Wu D,Ding K,Xu Y. (2018) Structure-Based Discovery and Optimization of Benzo[ d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC).. J Med Chem, 61 (7.0): (3037-3058). [PMID:29566488] |
| 102. Ghazy E,Zeyen P,Herp D,Hügle M,Schmidtkunz K,Erdmann F,Robaa D,Schmidt M,Morales ER,Romier C,Günther S,Jung M,Sippl W. (2020) Design, synthesis, and biological evaluation of dual targeting inhibitors of histone deacetylase 6/8 and bromodomain BRPF1.. Eur J Med Chem, 200 (112338-112338). [PMID:32497960] |
| 103. French, C A CA and 8 more authors.. (2001) BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19).. The American journal of pathology, [PMID:11733348] |
| 104. French, Christopher A CA and 5 more authors.. (2003) BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma.. Cancer research, (15): [PMID:12543779] |
| 105. Grimwood, Jane J and 97 more authors.. (2004) The DNA sequence and biology of human chromosome 19.. Nature, (1): [PMID:15057824] |
| 106. Jang, Moon Kyoo MK and 5 more authors.. (2005) The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription.. Molecular cell, (19): [PMID:16109376] |
| 107. You, Jianxin J and 6 more authors.. (2006) Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen interacts with bromodomain protein Brd4 on host mitotic chromosomes.. Journal of virology, [PMID:16940503] |
| 108. Parish, Joanna L JL, Bean, Angela M AM, Park, Regina B RB and Androphy, Elliot J EJ.. (2006) ChlR1 is required for loading papillomavirus E2 onto mitotic chromosomes and viral genome maintenance.. Molecular cell, (28): [PMID:17189189] |
| 109. Liu, Ying Y and 6 more authors.. (2008) Structural basis and binding properties of the second bromodomain of Brd4 with acetylated histone tails.. Biochemistry, (17): [PMID:18500820] |
| 110. Dephoure, Noah N and 6 more authors.. (2008) A quantitative atlas of mitotic phosphorylation.. Proceedings of the National Academy of Sciences of the United States of America, (5): [PMID:18669648] |
| 111. Huang, Bo B, Yang, Xiao-Dong XD, Zhou, Ming-Ming MM, Ozato, Keiko K and Chen, Lin-Feng LF.. (2009) Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA.. Molecular and cellular biology, [PMID:19103749] |
| 112. Hargreaves, Diana C; Horng, Tiffany and Medzhitov, Ruslan.. (2009) Control of inducible gene expression by signal-dependent transcriptional elongation.. Cell, (10): [PMID:19596240] |
| 113. Rigbolt, Kristoffer T G KT and 9 more authors.. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.. Science signaling, (15): [PMID:21406692] |
| 114. Rahman, Shaila S and 6 more authors.. (2011) The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3.. Molecular and cellular biology, [PMID:21555454] |
| 115. Wang, Ranran R, Li, Qing Q, Helfer, Christine M CM, Jiao, Jing J and You, Jianxin J.. (2012) Bromodomain protein Brd4 associated with acetylated chromatin is important for maintenance of higher-order chromatin structure.. The Journal of biological chemistry, (30): [PMID:22334664] |
| 116. Zhang, Weishi W and 11 more authors.. (2012) Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells.. The Journal of biological chemistry, (14): [PMID:23086925] |
| 117. Zhou, Houjiang H and 6 more authors.. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome.. Journal of proteome research, (4): [PMID:23186163] |
| 118. Wu, Shwu-Yuan SY, Lee, A-Young AY, Lai, Hsien-Tsung HT, Zhang, Hong H and Chiang, Cheng-Ming CM.. (2013) Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting.. Molecular cell, (7): [PMID:23317504] |
| 119. Floyd, Scott R SR and 23 more authors.. (2013) The bromodomain protein Brd4 insulates chromatin from DNA damage signalling.. Nature, (13): [PMID:23728299] |
| 120. Bian, Yangyang Y and 9 more authors.. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.. Journal of proteomics, (16): [PMID:24275569] |
| 121. Liu, Wen W and 7 more authors.. (2013) Brd4 and JMJD6-associated anti-pause enhancers in regulation of transcriptional pause release.. Cell, (19): [PMID:24360279] |
| 122. Jung, Marie M and 10 more authors.. (2014) Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1.. The Journal of biological chemistry, (28): [PMID:24497639] |
| 123. Gong, Fade F and 11 more authors.. (2015) Screen identifies bromodomain protein ZMYND8 in chromatin recognition of transcription-associated DNA damage that promotes homologous recombination.. Genes & development, (15): [PMID:25593309] |
| 124. Xiao, Zhenyu Z and 5 more authors.. (2015) System-wide Analysis of SUMOylation Dynamics in Response to Replication Stress Reveals Novel Small Ubiquitin-like Modified Target Proteins and Acceptor Lysines Relevant for Genome Stability.. Molecular & cellular proteomics : MCP, [PMID:25755297] |
| 125. Hendriks, Ivo A; Treffers, Louise W; Verlaan-de Vries, Matty; Olsen, Jesper V and Vertegaal, Alfred C O.. (2015) SUMO-2 Orchestrates Chromatin Modifiers in Response to DNA Damage.. Cell reports, (17): [PMID:25772364] |
| 126. Tanaka, Minoru M and 8 more authors.. (2016) Design and characterization of bivalent BET inhibitors.. Nature chemical biology, [PMID:27775715] |
| 127. Konuma, Tsuyoshi T and 8 more authors.. (2017) Structural Mechanism of the Oxygenase JMJD6 Recognition by the Extraterminal (ET) Domain of BRD4.. Scientific reports, (24): [PMID:29176719] |
| 128. Alpsoy, Aktan A and Dykhuizen, Emily C EC.. (2018) Glioma tumor suppressor candidate region gene 1 (GLTSCR1) and its paralog GLTSCR1-like form SWI/SNF chromatin remodeling subcomplexes.. The Journal of biological chemistry, (16): [PMID:29374058] |
| 129. Thomas R Burkard,Melanie Planyavsky,Ines Kaupe,Florian P Breitwieser,Tilmann Bürckstümmer,Keiryn L Bennett,Giulio Superti-Furga,Jacques Colinge. (2011-01-29) Initial characterization of the human central proteome.. BMC systems biology, 5 (17-17). [PMID:21269460] |
